Epimorphin deletion protects mice from inflammation-induced colon carcinogenesis and alters stem cell niche myofibroblast secretion

Anisa Shaker  
*Washington University School of Medicine in St. Louis*

Elzbieta A. Swietlicki  
*Washington University School of Medicine in St. Louis*

Lihua Wang  
*Washington University School of Medicine in St. Louis*

Shujun Jiang  
*Washington University School of Medicine in St. Louis*

Birce Onal  
*Washington University School of Medicine in St. Louis*

See next page for additional authors

Follow this and additional works at: [http://digitalcommons.wustl.edu/open_access_pubs](http://digitalcommons.wustl.edu/open_access_pubs)

Recommended Citation

Shaker, Anisa; Swietlicki, Elzbieta A.; Wang, Lihua; Jiang, Shujun; Onal, Birce; Bala, Shashi; DeSchryver, Katherine; Newberry, Rodney; Levin, Marc S.; and Rubin, Deborah C., "Epimorphin deletion protects mice from inflammation-induced colon carcinogenesis and alters stem cell niche myofibroblast secretion." The Journal of Clinical Investigation.120,6. 2081-2093. (2010).  
http://digitalcommons.wustl.edu/open_access_pubs/1635

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Epimorphin deletion protects mice from inflammation-induced colon carcinogenesis and alters stem cell niche myofibroblast secretion

Anisa Shaker,1 Elzbieta A. Swietlicki,1 Lihua Wang,1 Shujun Jiang,1 Birce Onal,1 Shashi Bala,1 Katherine DeSchryver,1 Rodney Newberry,1 Marc S. Levin,1,2 and Deborah C. Rubin1,3

1Department of Internal Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA. 2Department of Medicine, Saint Louis VA Medical Center, Saint Louis, Missouri, USA. 3Department of Developmental Biology, Washington University School of Medicine, Saint Louis, Missouri, USA.

Epithelial-mesenchymal interactions regulate normal gut epithelial homeostasis and have a putative role in inflammatory bowel disease and colon cancer pathogenesis. Epimorphin is a mesenchymal and myofibroblast protein with antiproliferative, promorphogenic effects in intestinal epithelium. We previously showed that deletion of epimorphin partially protects mice from acute colitis, associated with an increase in crypt cell proliferation. Here we explored the potential therapeutic utility of modulating epimorphin expression by examining the effects of epimorphin deletion on chronic inflammation–associated colon carcinogenesis using the azoxymethane/dextran sodium sulfate (AOM/DSS) model. We found that mice in which epimorphin expression was absent had a marked reduction in incidence and extent of colonic dysplasia. Furthermore, epimorphin deletion in myofibroblasts altered the morphology and growth of cocultured epithelial cells. Loss of epimorphin affected secretion of soluble mesenchymal regulators of the stem cell niche such as Chordin. Importantly, IL-6 secretion from LPS-treated epimorphin-deficient myofibroblasts was completely inhibited, and stromal IL-6 expression was reduced in vivo. Taken together, these data show that epimorphin deletion inhibits chronic inflammation–associated colon carcinogenesis in mice, likely as a result of increased epithelial repair, decreased myofibroblast IL-6 secretion, and diminished IL-6–induced inflammation. Furthermore, we believe that modulation of epimorphin expression may have therapeutic benefits in appropriate clinical settings.

Introduction

Dynamic and reciprocal epithelial-mesenchymal interactions play a critical role in intestinal morphogenesis, maintenance of the steady state between epithelial proliferation and differentiation along the crypt villus axis (1), and epithelial carcinogenesis (2, 3). The gut mesenchyme, which gives rise to subepithelial myofibroblasts as well as other stromal components (4), supports the normal growth and development of the endoderm and directs regional specificity in the gut (1, 5, 6). Mesenchymal stem cells (MSCs) likely play an important role in epithelial injury and repair (7–9). Intestinal subepithelial myofibroblasts are located in the lamina propria and are directly adjacent to the crypts, which contain epithelial stem and proliferating progenitor cells. Myofibroblasts secrete a variety of signaling molecules, growth factors, and soluble mediators of inflammation. These cells play a critical role in epithelial restitution and wound repair and contribute to modulation of the immune response, tissue fibrosis, and colonic tumorigenesis (3, 8, 10).

Epimorphin is a mesenchymal/myofibroblast protein that is a member of the syntaxin family of membrane bound, intracellular vesicle docking proteins known as t-SNAREs (11–13). Monomeric epimorphin (also referred to as syntaxin 2) has been detected intracellularly as a component of the SNARE machinery that targets secretory vesicles to the plasma membrane (13, 14). Studies of lung, skin, and mammary epithelium suggest a role for myofibroblast/stromal epimorphin in the formation of luminal, ductular, or branching structures during ontogeny (11, 15, 16). The molecular basis of the biologic function of epimorphin is complex, and investigations of its role in morphogenesis of the mammary epithelium have suggested that epimorphin has distinct, cell-specific extra- and intracellular roles (12, 16, 17).

We have previously shown that epimorphin is expressed by intestinal subepithelial myofibroblasts and that it exerts antiproliferative, promorphogenic effects on adjacent small intestinal epithelium (18). To precisely define its in vivo role, we generated epimorphin-deleted (Epim–/–) mice and showed that epimorphin regulates basal proliferation of small intestinal, but not colonic, epithelium (19). Neonatal Epim–/– mice have increased small bowel crypt depth, crypt cell proliferation, and crypt fission. The consequences of epimorphin deletion are mediated, at least in part, by effects on bone morphogenetic protein (BMP) and Wnt–β-catenin pathways (18, 19). Deletion of epimorphin partially protected the colon from injury in a dextran sodium sulfate–induced (DSS-induced) colitis model, associated with a marked increase in crypt cell proliferation (19). These studies suggested that effects of epimorphin deletion on downstream effector pathways may have potential therapeutic benefit for human inflammatory bowel disease (IBD). A critical complication of chronic gut inflammation from IBD is a markedly increased risk of colon cancer (20). To determine the long-term effect of epimorphin deletion in colitis-associated colon cancer, here
we examined the susceptibility of Epim–/– mice to chronic inflammation–induced carcinogenesis using the azoxymethane/DSS (AOM/DSS) model. Epimorphin deletion resulted in an increase in colonic crypt cell proliferation, yet markedly reduced dysplastic tumor burden. Absence of epimorphin profoundly affected myofibroblast secretory function and response to LPS, resulting in altered myofibroblast interactions with epithelium, in an in vitro coculture model. In vivo analysis revealed decreased BMP signaling and reduced IL-6 expression in AOM/DSS-treated Epim–/– colons. Our results suggest that the myofibroblast plays an important role in inflammation-induced colon cancer and that strategies to alter myofibroblast function may provide novel therapeutic avenues for the treatment of colitis and prevention of colitis-associated cancer.

Results

Epimorphin deletion markedly reduces dysplasia and polyposis in the AOM/DSS model of colon carcinogenesis. To determine the effects of epimorphin deletion on inflammation-induced dysplasia and carcinogenesis, we treated congeneric Epim–/– mice (C57BL/6J) and WT C57BL/6J mice with AOM (13.5 mg/kg) followed by 3 5-day cycles of 2.5%–3.0% DSS (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/JCI40676DS1). This regimen was chosen based on our pilot studies (see Methods) that showed that lower doses of AOM and DSS (21, 22) were ineffective in inducing dysplasia in WT and Epim–/– mice. The higher doses resulted in dysplasia in 11 of 11 WT mice and 10 of 11 Epim–/– mice, with a mortality rate of 50% (11 of 22) of WT mice and 35% (6 of 17) of Epim–/– mice (P = NS).

Induction of colitis in mice results in body weight loss. The percent body weight loss in Epim–/– mice was significantly reduced compared with WT mice after the completion of the second of 3 DSS treatments (Supplemental Figure 2).

The pattern and extent of polyposis was evaluated in all mice that survived the regimen (11 Epim–/– and 11 WT). Epim–/– mice had a markedly decreased tumor load, with a decrease in the percentage of total colonic surface area grossly replaced by tumor, compared with WT mice (WT, 14.45%; Epim–/–, 4.96%; P = 0.01; Figure 1A). Whereas all WT mice had polyps and dysplasia, 1 of 11 Epim–/– mice had no evidence of polyps and dysplasia. Polyposis in the WT mice was characterized grossly by multiple coalescing tumors with very small areas of intervening normal mucosa. In contrast, the Epim–/– polyposis phenotype consisted of scattered lesions throughout the descending colon, separated by wide areas of normal mucosa (Figure 1, B and C). Histological analysis by H&E staining revealed that in addition to gross polyposis, there were also areas of “flat” dysplastic change. The diameter of each area of dysplasia per field of vision was measured by ocular micrometer. In the WT mouse colon, the average diameter of the dysplastic area was 2,040 μm compared with 1,075 μm in Epim–/– mice (P < 0.01; Figure 1D). In addition, there was a decrease in the number of dysplastic lesions per field of vision in Epim–/– mice (14.8%; n = 11) compared with WT mice (32.6%; n = 11; P = 0.041; Figure 1E). 1 of 11 Epim–/– mice had dysplasia in the ascending colon in addition to the descending colon; 4 of 11 WT mice had dysplasia in the ascending colon or cecum in addition to the descending colon. There were no differences in the severity or grade of dysplasia between WT and Epim–/– mice.
plasia comparing WT with Epim–/– mice (Figure 1, F and G). In addition, the pattern of β-catenin immunostaining was similar, with nuclear accumulation only in areas of high-grade dysplasia (Supplemental Figure 3). Cyclin D1 expression was also similar (data not shown).

After brief exposure to DSS, Epim–/– mice exhibited a marked increase in colonic crypt cell proliferation (19). AOM/DSS-treated mice were injected with 5-BrdU 90 minutes prior to sacrifice, and the labeling index was calculated in nondysplastic areas of the cecum and the proximal and distal colon (Figure 2). There was a significant increase in crypt cell proliferation in Epim–/– versus WT mice in the cecum (Epim–/–, 14.64%; WT, 9.11%; *P* < 0.005) and distal colon (Epim–/–, 16.64%; WT, 11.15%; *P* = 0.051), with a trend toward an increase in the proximal colon. However, in dysplastic areas of descending colon, there were no differences in cellular proliferation per unit surface area (data not shown).

Areas of dysplastic and normal epithelium were evaluated for apoptotic rate. There was no change in apoptosis in Epim–/– compared with WT mice, although effects on apoptosis at an earlier stage in the disease process cannot be ruled out, since tissues were analyzed at the end of the AOM/DSS treatment period.

Epimorphin deletion in myofibroblasts alters the morphology and growth of cocultured Caco-2 cells. Epimorphin is abundantly expressed in intestinal myofibroblasts, a major source of epimorphin in the gut (19, 23). Immunohistochemical analysis of dysplastic colon revealed that epimorphin was expressed in stroma surrounding areas of dysplasia (Supplemental Figure 4).

To elucidate the mechanisms underlying the protection from epithelial dysplasia in Epim–/– mice, primary cultures of colonic myofibroblasts from Epim–/– and WT mice were established as described previously (see Methods and ref. 24). Myofibroblast phenotype was confirmed by immunocytochemistry showing robust expression of α-SMA and vimentin (Figure 3, A–D), minimal desmin expression, and absence of expression of epithelial cytokeratin 19 (data not shown), consistent with a colonic myofibroblast phenotype (3) and similar to well-characterized small bowel myofibroblasts (24). Colonic myofibroblasts from WT mice also expressed epimorphin and α-SMA, as determined by immunoblot (Figure 3E). As expected, myofibroblasts from Epim–/– mice did not express epimorphin, but produced abundant α-SMA.

To examine the effects of myofibroblasts on the morphology, proliferation, and differentiation of epithelium, we cocultured myofibroblasts with Caco-2 cells (Figure 4). Caco-2 cells have been routinely used in coculture models, as they adhere well to myofibroblasts, exhibit a differentiated enterocyte-like phenotype,
and provide reproducible colony morphology (1, 18). Caco-2 cells formed larger colonies on Epim−/− colon myofibroblasts compared with Caco-2 colonies grown on WT myofibroblasts, which were small and compact (Epim−/−, 128 μm colony diameter; WT, 76 μm colony diameter; P < 0.05; Figure 4, A–C). Morphologic analysis showed that Caco-2 cells seeded on WT myofibroblasts formed multiple discrete, spherical, compact, and pseudostratified colonies. In contrast, Epim−/− myofibroblasts formed an epithelial monolayer with only occasional small foci of pseudostratified epithelium (Figure 4, D and E). To eliminate the possibility that the morphologic differences were due to differences in adhesion of Caco-2 cells to myofibroblasts, the number of adherent versus floating cells was quantified from media of Epim−/− and WT myofibroblast–Caco-2 cocultures. No differences were noted at 24 or 72 hours after plating (data not shown).

Epimorphin deletion alters colonic myofibroblast expression of paracrine factors including components of BMP, Hedgehog (Hh), and Wnt signaling pathways. To further elucidate the molecular basis for the differences in dysplasia in Epim−/− compared with WT colon, gene expression profiling of Epim−/− versus WT colon myofibroblasts was performed using Agilent microarrays. The total number of genes induced or inhibited greater than 2-fold as a consequence of epimorphin deletion was 2,552 and 3,327, respectively. Because of the large number of genes that exhibited changes in expression, we focused on confirming changes in expression in gene families that encode stromal factors involved in the regulation of colonic epithelial proliferation. These included members of the TGF-β superfamily including the BMP, Hh, and Wnt families (Table 1). Changes in expression were confirmed by quantitative real-time polymerase RT-PCR (qRT-PCR; Supplemental Methods; n = 3 independent experiments). Additional key candidate genes for each signaling pathway were also evaluated by qRT-PCR. Of the TGF-β superfamily members, BMP4 expression was increased 2.1-fold in Epim−/− compared with WT myofibroblasts. Marked alterations in expression of BMP inhibitors was noted, including Chordin-1 (68-fold increase), Follistatin (10-fold decrease), and Noggin (64-fold decrease). Gremlin-2 expression was unchanged. Analysis of the Hh signaling pathway showed that expression of Hh family members including Hh-interacting protein (Hhip), Cyclin B1, Patched-2, and Gli-3 were all decreased. In the Wnt family, expression of the Wnt inhibitors Dkk2, Dkk3, and Sfrp4 was increased (2.9- to 6.2-fold); with a 1.5-fold decrease in Sfrp1. Because the fold change in expression of the BMP inhibitors was widely divergent in Epim−/− compared with WT myofibroblasts, we examined the relative expression levels of BMP4 and BMP inhibitors in WT and Epim−/− myofibroblasts (Figure 5) to determine which were the most abundantly expressed, and therefore might be the most physiologically relevant. There was abundant BMP4, Chordin-1, Follistatin, and Gremlin-2 mRNA expression in WT and Epim−/− myofibroblasts, but significantly lower basal Noggin expression compared with Chordin and BMP4 (P < 0.05; Figure 5). The changes in expression were highest for Chordin (68-fold increase) and Noggin (64-fold decrease; P < 0.05).

Epimorphin deletion results in increased production and secretion of members of the BMP pathway. BMP4 and Chordin protein expression in cell lysate and media was quantified by ELISA (Supplemental Methods). Chordin expression was significantly increased in Epim−/− compared with WT colon myofibroblasts (Figure 6A), and there was a 10-fold increase in Chordin protein secretion from Epim−/− versus WT colon myofibroblasts (Figure 6B; P < 0.05). In addition, BMP4 protein expression was higher in Epim−/− myofibroblasts compared with WT (P < 0.05), and BMP4 secretion from unstimulated Epim−/− myofibroblasts was 2-fold higher than WT, although the difference was not statistically significant (Epim−/−, 79.8 pg/ml; WT, 39.5 pg/ml; P = 0.058; Figure 6, C and D).

To determine whether the effect of myofibroblast epimorphin deletion on Caco-2 colon morphology is mediated by Chordin, Epim−/− and WT myofibroblasts were cocultured with Caco-2 cells in the presence and absence of Chordin as described previously (25), and Caco-2 colony diameter was measured. Addition of Chordin to WT cocultures increased Caco-2 colony size from 80 to 205 μm (P < 0.05; Figure 7). Observation by inverted phase microscopy indicated that addition of Chordin reproduced the phenotype of Caco-2 colonies cocultured with Epim−/− myofibro-
Caco-2 colonies grown on colon. These findings further suggest that epimorphin deletion in epithelium (Figure 8, C–F) compared with AOM/DSS-treated WT immunostaining in both normal, nondysplastic BMP2/4 antibody that detects BMP2 expression in colonic epithelial cells (26, 27) and BMP4 expression in stroma (27–29). BMP2 and BMP4 were expressed in WT and Epim–/– colon; in a subset of Epim–/– colon, a small increase in epithelial and stromal expression was noted (Supplemental Figure 5). As expected, the size of myofibroblasts was barely detectable, and was more than 10-fold lower than WT cells (Figure 9B). Despite abundant protein expression, Epim–/– myofibroblasts did not secrete IL-6 into the media, unlike WT cells (Figure 9C). The profound decrease in IL-6 secretion in response to LPS was not due to absence or downregulation of TLR expression. Myofibroblasts responded to LPS by increasing IL-6 mRNA and protein in both Epim–/– and WT myofibroblasts. In addition, TLR4 mRNA was expressed in myofibroblasts, and TLR4 mRNA levels were increased greater than 2-fold in Epim–/– compared with WT cells (data not shown).

IFN-γ expression was very low in both Epim–/– and WT colon myofibroblasts and was not altered in response to LPS (data not shown). TNF-α mRNA expression in WT and Epim–/– myofibroblasts was barely detectable, and was more than 10-fold lower than IL-6 expression. TNF-α protein was not detected in cell lysates, nor was it detectable in secreted form upon LPS stimulation in either WT or Epim–/– myofibroblasts (data not shown).

To correlate these in vitro findings in vivo, we performed immunohistochemical analysis of IL-6 expression in AOM/DSS-treated Epim–/– and WT colon (Figure 10). IL-6 expression in WT dysplastic colon (Figure 10A) and in normal nondysplastic areas (Figure 10, C and E) was strongest in the stroma, with weak but detectable expression in the epithelium (consistent with previously reported IL-6 expression patterns; ref. 31). In contrast, in dysplastic (Figure 10B) and adjacent nondysplastic colonic inflammatory response in IBD (30). To determine cytokine expression and secretory function in WT and Epim–/– myofibroblasts, cells were treated with LPS for 24 hours to mimic the colitis-induced inflammatory milieu. Expression of inflammatory mediators upregulated in acute DSS colitis (TNF-α, IL-6, IFN-γ) with key roles in colitis-associated colon carcinogenesis (31, 32) was evaluated by qRT-PCR. In response to LPS, IL-6 expression increased in WT and Epim–/– myofibroblasts compared with unstimulated myofibroblasts ($P < 0.05$; Figure 9A). After exposure to LPS, IL-6 mRNA expression in Epim–/– myofibroblasts was decreased compared with WT cells. However, IL-6 protein expression was increased in LPS-stimulated Epim–/– myofibroblasts compared with unstimulated Epim–/– cells, at levels exceeding those of LPS-stimulated WT cells (Figure 9B). Despite abundant protein expression, Epim–/– myofibroblasts did not secrete IL-6 into the media, unlike WT cells (Figure 9C). The profound decrease in IL-6 secretion in response to LPS was not due to absence or downregulation of TLR expression. Myofibroblasts responded to LPS by increasing IL-6 mRNA and protein in both Epim–/– and WT myofibroblasts. In addition, TLR4 mRNA was expressed in myofibroblasts, and TLR4 mRNA levels were increased greater than 2-fold in Epim–/– compared with WT cells (data not shown).

IFN-γ expression was very low in both Epim–/– and WT colon myofibroblasts and was not altered in response to LPS (data not shown). TNF-α mRNA expression in WT and Epim–/– myofibroblasts was barely detectable, and was more than 10-fold lower than IL-6 expression. TNF-α protein was not detected in cell lysates, nor was it detectable in secreted form upon LPS stimulation in either WT or Epim–/– myofibroblasts (data not shown).

To correlate these in vitro findings in vivo, we performed immunohistochemical analysis of IL-6 expression in AOM/DSS-treated Epim–/– and WT colon (Figure 10). IL-6 expression in WT dysplastic colon (Figure 10A) and in normal nondysplastic areas (Figure 10, C and E) was strongest in the stroma, with weak but detectable expression in the epithelium (consistent with previously reported IL-6 expression patterns; ref. 31). In contrast, in dysplastic (Figure 10B) and adjacent nondysplastic colonic

<table>
<thead>
<tr>
<th>Gene</th>
<th>Fold change mRNA Epim–/– vs. WT</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMP pathway</td>
<td></td>
</tr>
<tr>
<td>Bmp2</td>
<td>1.7</td>
</tr>
<tr>
<td>Bmp4</td>
<td>2.1$^A$</td>
</tr>
<tr>
<td>Chordin-1</td>
<td>68.3$^A$</td>
</tr>
<tr>
<td>Gremlin-2</td>
<td>1.1</td>
</tr>
<tr>
<td>Follistatin</td>
<td>$-9.7^A$</td>
</tr>
<tr>
<td>Noggin</td>
<td>$-64.1^A$</td>
</tr>
<tr>
<td>TGF-β2</td>
<td>2.0$^A$</td>
</tr>
<tr>
<td>TGF-β3</td>
<td>1.0</td>
</tr>
<tr>
<td>Smad5</td>
<td>1.0</td>
</tr>
<tr>
<td>Hh pathway</td>
<td></td>
</tr>
<tr>
<td>Hhip</td>
<td>$-100.0^A$</td>
</tr>
<tr>
<td>Cyclin81</td>
<td>$-2.6^A$</td>
</tr>
<tr>
<td>Patch-1</td>
<td>$-1.2$</td>
</tr>
<tr>
<td>Patch-2</td>
<td>$-1.9^A$</td>
</tr>
<tr>
<td>Gli-1</td>
<td>$-1.3$</td>
</tr>
<tr>
<td>Gli-2</td>
<td>1.4</td>
</tr>
<tr>
<td>Gli-3</td>
<td>$-1.5^A$</td>
</tr>
<tr>
<td>Wnt pathway</td>
<td></td>
</tr>
<tr>
<td>Fzd3</td>
<td>1.0</td>
</tr>
<tr>
<td>Sfrp1</td>
<td>$-1.5^A$</td>
</tr>
<tr>
<td>Sfrp4</td>
<td>6.2$^A$</td>
</tr>
<tr>
<td>Dkk2</td>
<td>4.4$^A$</td>
</tr>
<tr>
<td>Dkk3</td>
<td>2.9$^A$</td>
</tr>
</tbody>
</table>

Fold change in mRNA expression for each gene was determined by qRT-PCR. $n = 3$ independent experiments performed on primary myofibroblast cultures. $^A P < 0.05$. blasts, with a predominance of epithelial monolayers in the Chordin-treated cocultures (data not shown). As expected, the size of Caco-2 colonies grown on Epim–/– myofibroblasts was unchanged in the presence of additional exogenous Chordin ($P = NS$). These results suggested that increased Chordin secretion was at least partly responsible for the effect of epimorphin deletion on Caco-2 colony morphology.

To correlate these in vitro findings in vivo, we examined the expression of BMP2 and BMP4 as well as the primary end target of BMP signaling, p-Smad1/5/8. Sections of dysplastic colon from WT and Epim–/– myofibroblasts were incubated with an anti-BMP2/4 antibody that detects BMP2 expression in colonic epithelial cells (26, 27) and BMP4 expression in stroma (27–29). BMP2 and BMP4 were expressed in WT and Epim–/– colon; in a subset of Epim–/– colons, a small increase in epithelial and stromal expression was noted (Supplemental Figure 5).

To determine the net effect of epimorphin deletion on BMP signaling in vivo, we examined p-Smad1/5/8 expression by immunohistochemical analysis of AOM/DSS-treated Epim–/– and WT colons (Figure 8). There was a marked decrease in p-Smad1/5/8 immunostaining in both normal, nondysplastic Epim–/– colon (Figure 8, A and B) and dysplastic descending colon and rectal epithelium (Figure 8, C–F) compared with AOM/DSS-treated WT colon. These findings further suggest that epimorphin deletion in myofibroblasts results in net BMP inhibition. Epimorphin deletion blunts the colonic myofibroblast response to LPS. Cytokine release plays a key role in tissue damage and the inflammatory response in IBD (30). To determine cytokine expression and secretory function in WT and Epim–/– myofibroblasts, cells were treated with LPS for 24 hours to mimic the colitis-induced inflammatory milieu. Expression of inflammatory mediators upregulated in acute DSS colitis (TNF-α, IL-6, IFN-γ) with key roles in colitis-associated colon carcinogenesis (31, 32) was evaluated by qRT-PCR. In response to LPS, IL-6 expression increased in WT and Epim–/– myofibroblasts compared with unstimulated myofibroblasts ($P < 0.05$; Figure 9A). After exposure to LPS, IL-6 mRNA expression in Epim–/– myofibroblasts was decreased compared with WT cells. However, IL-6 protein expression was increased in LPS-stimulated Epim–/– myofibroblasts compared with unstimulated Epim–/– cells, at levels exceeding those of LPS-stimulated WT cells (Figure 9B). Despite abundant protein expression, Epim–/– myofibroblasts did not secrete IL-6 into the media, unlike WT cells (Figure 9C). The profound decrease in IL-6 secretion in response to LPS was not due to absence or downregulation of TLR expression. Myofibroblasts responded to LPS by increasing IL-6 mRNA and protein in both Epim–/– and WT myofibroblasts. In addition, TLR4 mRNA was expressed in myofibroblasts, and TLR4 mRNA levels were increased greater than 2-fold in Epim–/– compared with WT cells (data not shown).

IFN-γ expression was very low in both Epim–/– and WT colon myofibroblasts and was not altered in response to LPS (data not shown). TNF-α mRNA expression in WT and Epim–/– myofibroblasts was barely detectable, and was more than 10-fold lower than IL-6 expression. TNF-α protein was not detected in cell lysates, nor was it detectable in secreted form upon LPS stimulation in either WT or Epim–/– myofibroblasts (data not shown).

To correlate these in vitro findings in vivo, we performed immunohistochemical analysis of IL-6 expression in AOM/DSS-treated Epim–/– and WT colon (Figure 10). IL-6 expression in WT dysplastic colon (Figure 10A) and in normal nondysplastic areas (Figure 10, C and E) was strongest in the stroma, with weak but detectable expression in the epithelium (consistent with previously reported IL-6 expression patterns; ref. 31). In contrast, in dysplastic (Figure 10B) and adjacent nondysplastic colonic

![Figure 5](http://www.jci.org/content/120/6/2085/F5.large.jpg)
mucosa of AOM/DSS-treated Epim−/− mice (Figure 10, D and F), stromal IL-6 expression was markedly diminished compared with WT. Despite the decrease in stromal expression, pericryptal cells at the base of the crypts in Epim−/− mice showed expression of IL-6 (Figure 10F), consistent with their ability to synthesize but not secrete IL-6 (Figure 9C). Serum levels of IL-6 and TNF-α were measured by ELISA in AOM/DSS-treated Epim−/− and WT mice, and no significant differences were found (data not shown, n = 4 mice per group). Serum concentrations were measured in individual mice, and there was no correlation between tumor burden and serum cytokine levels. These results suggested that epimorphin deletion may not block IL-6 secretion from other cell types, e.g., from myeloid cells such as macrophages (which also express epimorphin; ref. 33) and dendritic cells. Because this population does not secrete measurable IL-6 at baseline, cells were treated with LPS for 24 hours, and IL-6 secretion was quantified. Epimorphin deletion did not change IL-6 secretion in response to LPS, which increased in both WT and Epim−/− bone marrow–derived dendritic cells (data not shown). These data suggest that epimorphin deletion reduces local IL-6 production from myofibroblasts, and, to a lesser extent, from macrophages, which are uniquely located adjacent to epithelium and the stem cell niche (9).

To rule out the possibility that compensatory changes in other syntins resulted in the altered secretory patterns in Epim−/− myofibroblasts, we examined expression of syntins 1a, 3, and 4, which have the highest percentage homology with epimorphin, and syntins 5 and 6, which are also expressed in myofibroblasts (ref. 37 and Supplemental Figure 7). No differences in mRNA expression were noted except for absence of epimorphin, as expected, in Epim−/− myofibroblasts.

To further evaluate the altered secretory patterns in Epim−/− myofibroblasts, electron microscopy was performed to analyze the ultrastructural morphology of Epim−/− and WT myofibroblasts (Figure 11). Parameters included nuclear to cytoplasmic ratios, nuclear membrane regularity and/or roundness, cytoplasmic membrane complexity, length and state of distention of the rough endoplasmic reticulum (RER), and mitochondria. There was an increase in long parallel stacks of RER in Epim−/− cells (Figure 11, A and B). In addition, the short stacks of RER were significantly more dilated in Epim−/− myofibroblasts (Figure 11C). Dilatation of RER is associated with increased accumulation of protein (38, 39), consistent with our findings that synthesis and secretion of IL-6 and a subset of BMP inhibitors were markedly altered by epimorphin deletion. There were no differences in the other morphologic parameters. Because these morphological findings were suggestive of ER stress (40), mRNA expression of the ER stress markers Xbp-1

Figure 6
Increased Chordin and BMP4 expression and secretion from Epim−/− myofibroblasts. Chordin (A and B) and BMP4 (C and D) expression and secretion were quantified in cell lysates (A and C) and in media (B and D) by ELISA as described in Methods. BMP4 expression in media was higher in Epim−/− versus WT myofibroblasts, although the difference was not significant (P = 0.058). *P < 0.05.

Figure 7
Chordin alters the morphology of cocultured epithelium. Chordin (2 μg/ml) was added to WT and Epim−/− colon myofibroblast–Caco-2 cocultures. Addition of Chordin to WT myofibroblast–Caco2 cocultures reproduced the morphology of Caco-2 cells cocultured with Epim−/− myofibroblasts. The diameter of Caco-2 colonies grown on WT myofibroblasts increased in the presence of Chordin (WT, 80 μm; WT plus Chordin, 205 μm) and were similar to the size of Caco-2 colonies grown on Epim−/− myofibroblasts. Addition of Chordin did not change Caco-2 colony size on Epim−/− myofibroblasts: Epim−/−, 219 μm; Epim−/− plus Chordin, 219 μm. *P < 0.05.
signaling activity is low. To determine the physiologic significance of the decreased expression of several Hh targets in Epim<sup>−/−</sup> myofibroblasts, myofibroblasts were incubated with recombinant sonic hedgehog (Shh) to determine whether there is also a blunted response to Hh signals. (Ihh and Shh are identical with respect to receptor binding and target gene activation; ref. 44). Expression of Hhip increased 3.5-fold (P < 0.05), Gli-1 increased 6.13-fold (P < 0.05), and Ptc-1 increased 2.8-fold (P = 0.07) in WT myofibroblasts treated with Shh. Epim<sup>−/−</sup> colon myofibroblasts treated with Shh had increased expression of Gli1 only (2.3-fold; P < 0.01); however, absolute levels of Gli1 remained 3.7-fold less than in WT (P < 0.005). Treatment with Shh did not induce Hhip and Ptc-1 expression in Epim<sup>−/−</sup> myofibroblasts (Figure 12).

**Discussion**

Deletion of epimorphin reduced the incidence and extent of dysplasia in the AOM/DSS model of inflammation-induced colon carcinogenesis. This protection from dysplasia was associated with increased crypt cell proliferation in adjacent nondysplastic Epim<sup>−/−</sup> epithelium. Epimorphin deletion also affected myofibroblast-epithelial interactions in vitro: WT myofibroblasts cocultured with epithelial Caco-2 cells exhibited small, compact Caco-2 colony morphology with a pseudostratified epithelium; in contrast, Caco-2 cells cocultured with Epim<sup>−/−</sup> myofibroblasts showed increased colony diameter and epithelial monolayer formation. Epimorphin deletion induced marked changes in expression and secretion of a subset of BMP inhibitors, resulting in a net decrease in colonic BMP signaling, as indicated by reduced p-Smad1/5/8 expression. The importance of BMP inhibition was further established by showing that addition of Chordin to WT myofibroblast–Caco-2 epithelial cocultures recapitulated the growth and morphology of Caco-2 colonies cocultured with Epim<sup>−/−</sup> myofibroblasts. Epimorphin deletion also resulted in a profound decrease in LPS-stimulated myofibroblast secretion of the proinflammatory cytokine IL-6, with reduced IL-6 expression in AOM/DSS-treated Epim<sup>−/−</sup> colon.

Electron microscopy of Epim<sup>−/−</sup> myofibroblasts depicted morphologic changes in the RER consistent with the marked alteration in synthesis and secretion of IL-6 and Chordin.

Our data suggest that the mechanisms by which epimorphin deletion results in protection from dysplasia are complex, and likely include enhanced epithelial repair resulting from episodic increased crypt cell proliferation as well as reduced epithelial cell damage caused by decreased inflammation. These changes appear to be mediated, at least in part, by inhibition of BMP and IL-6 signaling. In addition, because IL-6 has been postulated to regulate tumor stem cell proliferation, epimorphin deletion may also exert effects on tumorigenesis.

BMP, Wnt, Hh, and Notch signaling interplay in the stem cell niche to regulate intestinal crypt cell proliferation (29, 45–48). Our data showed that expression and secretion of a subset of soluble mesenchymal BMP pathway components were regulated by epimorphin deletion, resulting in decreased BMP signaling in vivo (Figure 8). BMPs and BMP inhibitors originate from the stroma and act on adjacent epithelium (27–29). Expression of these inhibitors is highest toward the base of the crypts, adjacent to the stem cell niche (49). BMPs inhibit crypt cell proliferation, presumably via effects on Wnt–β-catenin signaling mediated by the PTEN-P13K-Akt pathway (29), although the precise mechanisms are still being clarified (50). A balance between BMPs and BMP inhibitors is thought to play a role in maintaining normal basal levels of crypt cell proliferation (49).
Chordin’s key role is further supported by its effects in (Figures 5 and 6), it is likely that Chordin’s inhibitory actions are both of which result in a juvenile polyposis phenotype locally dominant in the crypt due to its 10-fold increased secretion. BMP receptor BMPR1A (51), or in Noggin-overexpressing mice in a tumorigenic phenotype, as in mice that have a nonfunctional BMP inhibition stimulates enhanced crypt cell proliferation early in the course of AOM/DSS-induced disease, resulting in enhanced expression. Complete BMP inhibition might be expected to result in a tumorigenic phenotype, as in mice that have a nonfunctional BMP receptor BMPR1A (51), or in Noggin-overexpressing mice (27, 28), both of which result in a juvenile polyposis phenotype and markedly enhanced epithelial proliferation rate. Although BMP inhibition is likely to result in unopposed Wnt signaling, epimorphin deletion resulted in decreased dysplasia. We postulate that in our model, BMP inhibition results in enhanced epithelial repair and that this, in conjunction with markedly reduced IL-6 secretion, leads to partial protection from dysplasia.

Epimorphin deletion completely blocked IL-6 secretion by myofibroblasts, and in vivo analysis of IL-6 expression in Epim–/– mice, and WT dysplasia in the AOM/DSS model demonstrates that epimorphin deletion results in diminished stromal IL-6 expression. We also showed that epimorphin deletion reduced IL-6 secretion by peritoneal macrophages, but not by bone marrow–derived dendritic cells. Reduced stromal IL-6 likely results in decreased epithelial cell damage (38). In addition, IL-6 is active in the tumor stem cell niche (52); reduced secretion may also result in decreased proliferation of dysplastic premalignant cells, thus suggesting a direct effect on tumorigenesis (31, 52). Our data are consistent with studies from other laboratories (31, 32, 53) that have shown that IL-6 plays a key role in the pathogenesis of colitis-associated carcinogenesis. The pleiomorphic effects of epimorphin deletion on secretion of multiple factors, particularly IL-6, likely explains why the observed increase in colonic crypt cell proliferation did not result in larger tumors, as in other genetic models of chronic inflammation–associated carcinogenesis, such as the SOCS3-null mouse (32). It is likely that the end result of epimorphin deletion is a change in secretion of soluble factors that overall has beneficial effects, resulting in reduced dysplasia.

Wnt signaling is critically important in regulating normal crypt cell proliferation and is dysregulated in colon carcinogenesis. In colitis-associated neoplasia, Apc mutations are much less common compared with sporadic colon cancer and occur later in the disease (20, 54). Both epithelial and mesenchymal cells express Wnts (55), but the precise sources and regulation of Wnt secretion are still being clarified. Expression of several Wnt inhibitors was upregulated in Epim–/– myofibroblasts. However, epimorphin deletion did not alter expression of nuclear β-catenin or cyclin D1 in dysplastic tumors and did not affect the proportion of low- and high-grade dysplastic lesions. The significance of the change in expression of Wnt inhibitors is unclear from our studies, which evaluated Wnt target gene expression at an advanced stage of the disease process. Following Apo mutation, nuclear β-catenin signaling becomes dysregulated, and changes in Wnt ligand expression may no longer affect downstream signaling; however, it is possible that enhanced secretion of Wnt inhibitors earlier in the disease course, prior to Apo mutation, may diminish proliferation of dysplastic epithelium.

The net effect of epimorphin deletion is inhibition of BMP signaling in the epithelium, as indicated by decreased p-Smad1/5/8 expression (Figure 8). This would be expected to lead to an increase in crypt cell proliferation, as shown in Figure 2. Although expression of a subset of BMP inhibitors is decreased in Epim–/– myofibroblasts (Figure 5), and BMP4 expression and secretion were increased (Figures 5 and 6), it is likely that Chordin’s inhibitory actions are locally dominant in the crypt due to its 10-fold increased secretion. Chordin’s key role is further supported by its effects in Epim–/– myofibroblast cocultures (Figure 7). We postulate that in Epim–/– mice, BMP inhibition stimulates enhanced crypt cell proliferation early in the course of AOM/DSS-induced disease, resulting in enhanced epithelial repair and decreased tumorigenesis.

Our model appears to result in partial, but not complete, BMP inhibition, as indicated by persistent, albeit reduced, p-Smad1/5/8 expression. Complete BMP inhibition might be expected to result in a tumorigenic phenotype, as in mice that have a nonfunctional BMP receptor BMPR1A (51), or in Noggin-overexpressing mice (27, 28), both of which result in a juvenile polyposis phenotype and markedly enhanced epithelial proliferation rate. Although BMP inhibition is likely to result in unopposed Wnt signaling, epimorphin deletion resulted in decreased dysplasia. We postulate that in our model, BMP inhibition results in enhanced epithelial repair and that this, in conjunction with markedly reduced IL-6 secretion, leads to partial protection from dysplasia.

Epimorphin deletion completely blocked IL-6 secretion by myofibroblasts, and in vivo analysis of IL-6 expression in Epim–/– and WT dysplasia in the AOM/DSS model demonstrates that epimorphin deletion results in diminished stromal IL-6 expression. We also showed that epimorphin deletion reduced IL-6 secretion by peritoneal macrophages, but not by bone marrow–derived dendritic cells. Reduced stromal IL-6 likely results in decreased epithelial cell damage (38). In addition, IL-6 is active in the tumor stem cell niche (52); reduced secretion may also result in decreased proliferation of dysplastic premalignant cells, thus suggesting a direct effect on tumorigenesis (31, 52). Our data are consistent with studies from other laboratories (31, 32, 53) that have shown that IL-6 plays a key role in the pathogenesis of colitis-associated carcinogenesis. The pleiomorphic effects of epimorphin deletion on secretion of multiple factors, particularly IL-6, likely explains why the observed increase in colonic crypt cell proliferation did not result in larger tumors, as in other genetic models of chronic inflammation–associated carcinogenesis, such as the SOCS3-null mouse (32). It is likely that the end result of epimorphin deletion is a change in secretion of soluble factors that overall has beneficial effects, resulting in reduced dysplasia.

Wnt signaling is critically important in regulating normal crypt cell proliferation and is dysregulated in colon carcinogenesis. In colitis-associated neoplasia, Apc mutations are much less common compared with sporadic colon cancer and occur later in the disease (20, 54). Both epithelial and mesenchymal cells express Wnts (55), but the precise sources and regulation of Wnt secretion are still being clarified. Expression of several Wnt inhibitors was upregulated in Epim–/– myofibroblasts. However, epimorphin deletion did not alter expression of nuclear β-catenin or cyclin D1 in dysplastic tumors and did not affect the proportion of low- and high-grade dysplastic lesions. The significance of the change in expression of Wnt inhibitors is unclear from our studies, which evaluated Wnt target gene expression at an advanced stage of the disease process. Following Apo mutation, nuclear β-catenin signaling becomes dysregulated, and changes in Wnt ligand expression may no longer affect downstream signaling; however, it is possible that enhanced secretion of Wnt inhibitors earlier in the disease course, prior to Apo mutation, may diminish proliferation of dysplastic epithelium.

The net effect of epimorphin deletion is inhibition of BMP signaling in the epithelium, as indicated by decreased p-Smad1/5/8 expression (Figure 8). This would be expected to lead to an increase in crypt cell proliferation, as shown in Figure 2. Although expression of a subset of BMP inhibitors is decreased in Epim–/– myofibroblasts (Figure 5), and BMP4 expression and secretion were increased (Figures 5 and 6), it is likely that Chordin’s inhibitory actions are locally dominant in the crypt due to its 10-fold increased secretion. Chordin’s key role is further supported by its effects in Epim–/– myofibroblast cocultures (Figure 7). We postulate that in Epim–/– mice, BMP inhibition stimulates enhanced crypt cell proliferation early in the course of AOM/DSS-induced disease, resulting in enhanced epithelial repair and decreased tumorigenesis.

Our model appears to result in partial, but not complete, BMP inhibition, as indicated by persistent, albeit reduced, p-Smad1/5/8 expression. Complete BMP inhibition might be expected to result in a tumorigenic phenotype, as in mice that have a nonfunctional BMP receptor BMPR1A (51), or in Noggin-overexpressing mice (27, 28), both of which result in a juvenile polyposis phenotype and markedly enhanced epithelial proliferation rate. Although BMP inhibition is likely to result in unopposed Wnt signaling, epimorphin deletion resulted in decreased dysplasia. We postulate that in our model, BMP inhibition results in enhanced epithelial repair and that this, in conjunction with markedly reduced IL-6 secretion, leads to partial protection from dysplasia.

Epimorphin deletion completely blocked IL-6 secretion by myofibroblasts, and in vivo analysis of IL-6 expression in Epim–/– and WT dysplasia in the AOM/DSS model demonstrates that epimorphin deletion results in diminished stromal IL-6 expression. We also showed that epimorphin deletion reduced IL-6 secretion by peritoneal macrophages, but not by bone marrow–derived dendritic cells. Reduced stromal IL-6 likely results in decreased epithelial cell damage (38). In addition, IL-6 is active in the tumor stem cell niche (52); reduced secretion may also result in decreased proliferation of dysplastic premalignant cells, thus suggesting a direct effect on tumorigenesis (31, 52). Our data are consistent with studies from other laboratories (31, 32, 53) that have shown that IL-6 plays a key role in the pathogenesis of colitis-associated carcinogenesis. The pleiomorphic effects of epimorphin deletion on secretion of multiple factors, particularly IL-6, likely explains why the observed increase in colonic crypt cell proliferation did not result in larger tumors, as in other genetic models of chronic inflammation–associated carcinogenesis, such as the SOCS3-null mouse (32). It is likely that the end result of epimorphin deletion is a change in secretion of soluble factors that overall has beneficial effects, resulting in reduced dysplasia.

Wnt signaling is critically important in regulating normal crypt cell proliferation and is dysregulated in colon carcinogenesis. In colitis-associated neoplasia, Apc mutations are much less common compared with sporadic colon cancer and occur later in the disease (20, 54). Both epithelial and mesenchymal cells express Wnts (55), but the precise sources and regulation of Wnt secretion are still being clarified. Expression of several Wnt inhibitors was upregulated in Epim–/– myofibroblasts. However, epimorphin deletion did not alter expression of nuclear β-catenin or cyclin D1 in dysplastic tumors and did not affect the proportion of low- and high-grade dysplastic lesions. The significance of the change in expression of Wnt inhibitors is unclear from our studies, which evaluated Wnt target gene expression at an advanced stage of the disease process. Following Apo mutation, nuclear β-catenin signaling becomes dysregulated, and changes in Wnt ligand expression may no longer affect downstream signaling; however, it is possible that enhanced secretion of Wnt inhibitors earlier in the disease course, prior to Apo mutation, may diminish proliferation of dysplastic epithelium.
proliferation in the responsiveness to Hh signals contributes to enhanced crypt cell proliferation in the Epim−/− mice, but further studies are required to interrogate this complex pathway.

We have shown that the function of Epim−/− myofibroblasts was profoundly altered, resulting in marked changes in myofibroblast secretory function. These effects are likely due to epimorphin’s role as a syntaxin. These membrane-bound proteins have an intracellular, cytoplasmic orientation and are involved in trafficking of secretory vesicles. Our data suggest epimorphin deletion results in marked and specific alteration in secretory function, indicating that particular syntaxins may regulate the release of a subset of secreted proteins. Altered secretory function was not caused by compensatory changes in expression of other syntaxins in Epim−/− myofibroblasts (Supplemental Figure 7) or in Epim−/− intestine (19). IL-6 secretion from WT myofibroblasts was stimulated in response to LPS, but completely blocked in Epim−/− myofibroblasts. This occurred despite an increase in IL-6 mRNA and protein production in both Epim−/− and WT cells, suggesting a profound alteration in the IL-6 secretory process. In contrast, Chordin and BMP4 secretion were increased. The consequences of epimorphin deletion may be pathway dependent, and appear to differ in stimulated versus constitutive secretory processes. In the mammary gland, epimorphin is itself secreted (12, 17). However, immunoblot of concentrated media from WT myofibroblasts showed virtually no secretion of epimorphin, despite abundant cellular protein expression (data not shown).

Epim−/− myofibroblasts showed decreased expression of Hh target genes after exposure to Hh ligands compared with WT myofibroblasts. These data suggest that deletion of epimorphin also affects the myofibroblast’s ability to respond to soluble factors that signal to the mesenchyme. Unlike in other epithelial cancers, in which activated Hh signaling results in increased proliferation, active Hh signaling has been shown to inhibit crypt cell proliferation in the colon and small bowel (46). It is possible that this change in responsiveness to Hh signals contributes to enhanced crypt cell proliferation in the Epim−/− mice, but further studies are required to interrogate this complex pathway.

Overall, our data suggest that protection from dysplasia is likely mediated, at least in part, by changes in the function and secretory profile of intestinal subepithelial myofibroblasts. Our results suggest potentially novel pathogenetic mechanisms of inflammation-induced colonic dysplasia, which may be relevant for patients with IBD. Our data suggest that the stromal environment, including the myofibroblast, plays a significant role in inflammation-induced dysplasia. Although stromal interactions with the epithelium have been suggested to play a pathogenic role in colorectal carcinogenesis and inflammation-induced colon cancer, the epimorphin deletion mouse model is unique because myofibroblast secretory function has been altered. MSCs have been increasingly recognized to play an important role in wound repair in epithelial tissues (7, 8, 56). Whether the MSC or a more differentiated progeny cell is responsible for cross-talk within the stem cell niche is unclear. Our studies suggest that the myofibroblast may be one of the MSC progeny that is active within the stem cell niche. These studies also suggest what we believe to be a novel therapeutic target for treatment of IBD and prevention of colorectal cancer, since modifying myofibroblast function appears to affect epithelial cell proliferation and the incidence and severity of dysplasia.

In summary, epimorphin deletion showed beneficial effects in 2 colitis/injury models, the acute DSS-induced colitis model (19) and the AOM/DSS model of colitis-associated carcinogenesis, which suggests that modulating the function of this myofibroblast protein may have a therapeutic effect in the appropriate clinical setting. Our results confirm the complexity of mesenchymal-epithelial interactions and suggest a role for myofibroblasts in colonic injury, repair, and carcinogenesis. We have shown that, in the AOM/DSS model, an intervention resulting in increased crypt cell proliferation may still have beneficial effects even in the long term. Thus, therapies that increase epithelial repair and crypt cell proliferation while reducing inflammatory damage may have a place in the IBD/
chronic inflammatory disorder armamentarium. Since epimorphin is widely expressed in the stroma of other epithelial tissues, these data may have relevance to other inflammation-induced epithelial cancers, such as those in pancreas, esophagus, and skin.

**Methods**

**Animals.** Epim−/− mice, with a global deletion of epimorphin, were generated as described previously (19), and C57BL/6J WT littermates or C57BL/6J mice purchased from Jackson Laboratory were used as controls. Mice purchased from Jackson Laboratory were acclimated to the animal facility for 3.5 weeks. Mice were housed in a 12-hour light/dark cycle with free access to food and water. Mice were fed a standard rodent chow diet (PicoLab 20; Purina). Age-matched 8- to 12-week-old Epim−/− mice and their WT littermates were used in all experiments. All animal experimentation was approved by the Animal Studies Committee of Washington University School of Medicine.

**AOM/DSS model for colitis-induced carcinogenesis.** Congenic Epim−/− mice (on a C57BL/6J background; n = 17) and WT C57BL/6J mice (n = 22) were injected with AOM (13.5 mg/kg; Sigma-Aldrich) on day 0 (Supplemental Figure 1). On day 5, 3 cycles of DSS (2.5%, 3%, 3% in drinking water; 5 days/cycle) were initiated, each separated by 15 days of vehicle control (water). This regimen was chosen based on pilot studies showing that a previously published lower-dose regimen (21, 22) of AOM (12.5 mg/kg) followed by 3 cycles of 2.5%, 2.5%, 2% DSS in drinking water did not result in dysplasia in our mice. Mice were sacrificed 20 days after completion of the third DSS cycle, and tissues were placed into 10% formalin for histology. The presence and grade of dysplasia (low versus high grade) was evaluated as described previously (57). Apoptosis was evaluated by routine histologic methods on H&E-stained tissue (58). Serum was collected, and ELISA was performed per the manufacturers’ instructions for TNF-α, IFN-γ (BD Biosciences), and IL-6 (eBioscience).

**Crypt cell proliferation.** At 90 minutes prior to sacrifice, mice were injected intraperitoneally with 5-BrdU (8 g/l) and 5-fluorodeoxyuridine (0.8 g/l), total dose 120 mg/kg. 5-BrdU was detected with a monoclonal anti-BrdU antibody (Zymed Laboratories Inc.), and crypt cell proliferation was assessed as described previously (19). To correct for differences in crypt depth, labeling index was calculated as the number of 5-BrdU–positive cells per total crypt cell number (19). Crypt cell proliferation indices were also quantified separately in areas adjacent to ulcerations and were compared in WT and Epim−/− mice.

**Quantification of polyposis and dysplasia.** Grossly visible polyps were counted and diameters measured. Tumor area and total colon area were measured using Metaview software, and the percentage of tumor area per total colon area was calculated. Colons were divided into cecum, proximal, and distal colon, sectioned, and stained with H&E. The entire colon was analyzed for dysplasia by light microscopy (magnification, ×40; the presence of dysplasia was confirmed under higher-power magnification, ×100). The number of fields of vision was counted, and the percentage with dysplasia was calculated as the number of dysplastic segments per fields of vision. The diameter of dysplastic lesions was measured with Axiovision software (Zeiss).

**Generation of Epim−/− and WT colon myofibroblast primary cultures.** 3 Epim−/− and 3 WT colon myofibroblast primary cultures were established as previously described (24, 59) from WT and Epim−/− 7- to 9-day-old mice. Briefly, colon from cecum to rectum was placed in HBSS (Invitrogen), washed briefly, transferred into fresh HBSS, and minced into 2- to 3-mm pieces. Tissue was washed 8 times with HBSS by vigorous shaking, allowing for fragments of colon to sediment out; incubated with 300 U/ml collagenase XI (Sigma-Aldrich) and 0.1 mg/ml dispase (Gibco, Invitrogen) for 25 minutes at room temperature.
myofibroblasts between passages 6–9, cultured for 1 week. Total RNA from which probes were generated was prepared from a pool of 3 myofibroblast isolates for each. Probes were hybridized to Agilent microarrays as per the Genomics Core of the Digestive Diseases Research Core Center (DDRCC, Washington University School of Medicine). The data set was searched to identify putative epimorphin targets that exhibited greater than 2-fold increase or less than 0.5-fold decrease in expression between Epim−/− and WT colon myofibroblasts (GenePix 6.0 acquisition and analysis software; ref. 18), focusing on members of the BMP/TGF-β, Wnt, and Hh families. Changes in expression of selected genes on microarray were all confirmed by qRT-PCR.

Immunocytochemistry. Primary cultures of colonic myofibroblasts and Caco-2 cell lines were grown on chamber slides (Nalge Nunc International) and fixed in 10% formalin (room temperature) for 10 minutes, permeabilized with ice-cold methanol, and stored at −20°C. After incubation in blocking solution containing 5% BSA and 3% milk in Tris buffer (20 mM Tris HCl; 150 mM NaCl, pH 7.4; and 0.05% Tween 30) for 60 minutes, slides were incubated with primary antibody diluted in blocking solution overnight. To confirm the myofibroblast phenotype, rabbit polyclonal antibodies to α-SMA (ab5694, 1:200 dilution; Abcam); desmin (D8281, 1:100 dilution; Sigma-Aldrich); cytokeratin 18 (1:100 dilution; Millipore Corp.); vimentin (V4630, 1:100 dilution; Sigma-Aldrich) were used. Secondary antibody labeled with fluorescein or Cy3 diluted in blocking solution was applied for 1 hour at room temperature. Cells were mounted in Vectashield Mounting Medium with DAPI and examined under a fluorescence microscope (Axioskop 2; Carl Zeiss Jena GmbH).

Immunohistochemical analyses. Epimorphin expression in WT colon was analyzed as described previously (19) using a polyclonal rabbit anti–synactin 2 antibody (1:500 dilution; Synaptic Systems) that was purified to remove cross-reactivity with other synaptins, by preabsorption with total protein isolated from Epim−/− mouse intestine (1 μg antibody incubated with 50 μg protein). Epitope retrieval was with the Nuclear DECLOAKER reagent (BIOCARE) in a decloaking chamber. Primary antibody was applied overnight at 4°C. Antigen antibody complexes were detected with biotinylated goat anti-rabbit IgG (1:2,000 dilution) and donkey anti-goat IgG (1:2,000 dilution; Jackson ImmunoResearch Laboratories Inc.) and streptavidin–horseradish peroxidase with tyramide amplification, then developed in diaminobenzidine.

BMP2/BMP4 expression was detected as described previously (19) using a polyclonal rabbit anti-human BMP2/4 antibody (1:300 dilution; R&D Systems) that cross-reacts with mouse, and antigen retrieval with citraconic anhydride. p-Smad1/5/8, nuclear β-catenin, and cyclin D1 expression was detected using a polyclonal rabbit anti–p-Smad1/5/8 (1:100 dilution; Millipore), polyclonal rabbit anti-β-catenin antibody (1:600 dilution; BD Transduction Laboratories), and rabbit anti–cyclin D1 antibodies (1:200; Santa Cruz). Antigen retrieval for p-Smad1/5/8, nuclear β-catenin, and cyclin D1 expression was applied for 1 hour at room temperature. Cells were mounted in Vectashield Mounting Medium with DAPI and examined under a fluorescence microscope (Axioskop 2; Carl Zeiss Jena GmbH).

**Figure 12**
Epimorphin deletion alters hedgehog signaling. WT and Epim−/− colon myofibroblasts were incubated with recombinant Shh (0.9 μg/ml) for 24 hours, and mRNA levels of Hh end targets Hhip, Gli-1, and Patched-1 were quantified by qRT-PCR. WT myofibroblasts responded to Shh with an increase in Hhip (A), Gli-1 (B), and Patched-1 (C) mRNA (the difference in Patched-1 levels between treated and untreated WT was not significant; P = 0.07). Unlike Gli-1 mRNA, Hhip and Patched-1 expression did not increase in Epim−/− myofibroblasts in response to Shh, and expression of all 3 end targets in Shh-treated Epim−/− myofibroblasts was less than that in Shh-treated WT myofibroblasts. *P ≤ 0.05 versus WT; †P < 0.05 versus untreated Epim−/−; ‡P < 0.05 versus Shh-treated WT.
was performed with Diva Decloaker reagent (BIOCARE). Antigen-antibody complexes were detected with biotinylated goat anti-rabbit IgG (1:500 dilution; PerkinElmer), streptavidin–horseradish peroxidase, and diaminobenzidine. IL-6 expression was detected using a goat anti-combinant mouse IL-6 antibody (1:50 dilution; R&D systems) followed by a biotinylated donkey anti-goat antibody (1:500 dilution;Jackson ImmunoResearch Laboratories), streptavidin–horseradish peroxidase, and diaminobenzidine.

LPS stimulation of myofibroblasts. Epim–/– and WT colon myofibroblasts were seeded at a density of 2 × 10⁴ cells per well in 6-well plates and grown to 85% confluence. Cultured myofibroblasts were incubated with LPS (2.5, 5, and 10 μg/ml in serum-free media) for 6 hours (List Biological Laboratories Inc.). Based on this dose response, cells were incubated for 24 hours with LPS (5 μg/ml). Supernatant was collected for ELISA. Cells were harvested for RNA and protein for qRT-PCR and ELISA as described above and in Supplemental Methods. qRT-PCR data was expressed as fold induction relative to untreated samples.

Resident peritoneal macrophage isolation. Resident peritoneal macrophages were isolated by flushing the peritoneal cavity with cold PBS as described previously (35, 36, 60). Cells were counted for viability by trypan blue exclusion; plated (5 × 10⁵ cells/well) in a 96-well plate in RPMI 1640 media (BioWhittaker) with 2 mM L-glutamine (Life Technologies), 10 mM HEPES, 1 mM sodium pyruvate (BioWhittaker), 50 U/ml penicillin and 50 mg/ml streptomycin (Life Technologies), 50 mM 2-ME (Fisher Scientific), and 10% FCS (HyClone); and cultured at 37°C in 5% CO₂. After 24 hours, supernatants were collected for determination of IL-6 secretion by ELISA (Supplemental Methods).

Generation of bone marrow–derived dendritic cells. Dendritic cells were generated from mouse bone marrow progenitors as described previously (61). Bone marrow cells were harvested from femurs of Epim–/– and WT mice (n = 2) and cultured in 6-well plates with GM-CSF (10 ng/ml) and IL-4 (0.3 ng/ml) in RPMI 1640 media supplemented as described above. Media containing GM-CSF and IL-4 was replaced on days 3 and 4 of culture. On day 7, cells were harvested; a portion was evaluated by flow cytometry to confirm the generation of dendritic cells. Remaining dendritic cells were plated in 96-well plates (5 × 10⁴ cells/well) and treated with LPS (1 mg/ml) for 24 hours. Cells were harvested for RNA isolation, and supernatant was collected for evaluation of IL-6 secretion by ELISA.

SHH signaling in myofibroblasts. Epim–/– and WT colon myofibroblasts were seeded at a density of 2 × 10⁴ cells/well in 6-well plates and grown to 85% confluence. Cells were incubated with recombinant mouse SHH aminoterminal peptide (0.9 ng/ml; R&D Systems) in serum-free media for 6 hours (List Biological Laboratories). Supernatant was collected for ELISA. Cells were harvested, and RNA was isolated for qRT-PCR.

Myofibroblasts–Caco-2 coculture experiments. Epim–/– and WT colon myofibroblasts were plated as previously described (ref. 18; 1 × 10⁵ cells/well) and cultured for 3 days in 6-well plates (Costar Corning Inc). Caco-2 cells were seeded on top of subconfluent layers of myofibroblast cells (3 × 10⁴ cells/well). To assess adherence of the Caco-2 cells to the Epim–/– and WT myofibroblasts, media was collected at 24 and 72 hours after plating, and cells were counted; no differences in cell adherence were found (n = 2 experiments). Cocultures were examined daily by inverted phase microscopy, and photomicrographs were taken on day 4 after plating. To quantify differences in Caco-2 colony size and assess morphology, photomicrographs were taken from 4 quadrants per well. The diameter of each Caco-2 colony was measured using Axiovision software (Zeiss). After 7 days, cocultures were fixed in paraformaldehyde and processed for histology.

Chordin (2 μg/ml; R&D Systems) was added to media immediately after Caco-2 cells were seeded and again on day 3 of coculture. Morphology and colony diameters were measured on day 4 as described above.

Electron microscopic analysis. Epim–/– and WT colon myofibroblasts were grown to confluence in T25 flasks (n = 2 independent experiments), harvested with trypsin/EDTA, fixed with 2.5% glutaraldehyde, and processed for electron microscopy by the Electron Microscopy Core, Washington University School of Medicine. A total of 20 Epim–/– cells and 15 WT cells were observed at ×3,000 and ×4,400 magnification, and images were obtained from several quadrants of each section. Nuclear/cyttoplasmic ratio, nuclear membrane regularity and roundness, cytoplasmic membrane complexity, length of the rough ER, and mitochondria were evaluated in a semiquantitative manner, using magnification prints and a transparent 0.2-cm grid. A total of 48 prints were scored. The state of dilation of the short stacks of rough ER was assessed for 16 Epim–/– and 11 WT cells. Each cell was divided into 4 quadrants. The width of 3–5 stacks of rough ER in each quadrant was measured using the transparent grid, and the average width of rough ER was calculated for each quadrant. Images were independently reviewed by a pathologist blinded to the genotype.

Statistics. Data comparing Epim–/– and WT mice are presented as mean ± SEM, and significance was analyzed by 2-tailed Student’s t test (Microsoft Excel; Microsoft). P values less than or equal to 0.05 were considered significant. Mortality rates were compared in Epim–/– and WT mice using the Fisher exact probability test (Vassarstats).

Acknowledgments

We thank Kymberei Carter for help with immunostaining; Marilyn Levy (Electron Microscopy Core, Department of Cell Biology, Washington University School of Medicine), Valerie Blanc, and Keeley McDonald for advice and technical assistance; and Nicholás Davidson for advice and manuscript review. These studies were supported by NIH National Institute of Diabetes and Digestive and Kidney Diseases (NIDDDK) grants DK61216, DK46122 (D.C. Rubin), and DK50466 (M.S. Levin); by an American Gastroenterological Association Fellowship to Faculty Transition Award and a DDRCC Pilot and Feasibility award (A. Shaker); and by NIH NIDDK grant DK52574 (Morphology and Mouse Models Cores, DDRCC, Washington University School of Medicine).

Received for publication August 3, 2009, and accepted in revised form March 3, 2010.

Address correspondence to: Deborah C. Rubin, Division of Gastroenterology, Washington University School of Medicine, 660 South Euclid Avenue, Box 8124, St. Louis, Missouri 63110, USA. Phone: 314.362.8935; Fax: 314.362.8959; E-mail: drubin@wustl.edu.